| Stellaromics–Catalyst4: investment, 202502 financing round Series B totalling $80m incl lead investor Catalyst4 |
2025-02-11 |
| Stellaromics–SEVERAL: investment, 202502 financing round Series B $80m led by Catalyst4 |
2025-02-11 |
| Stellaromics–Stanford Univ: investment, 202502 financing round Series B totalling $80m incl co-investor Stanford University Ventures |
2025-02-11 |
| Akribion–Bruker: investment, 202502 seed financing round totalling €8m incl co-investor Bruker Invest |
2025-02-04 |
| Akribion–High-Tech Gründerfonds: investment, 202502 seed financing round totalling €8m incl co-investor HTGF |
2025-02-04 |
| Akribion–SEVERAL: investment, 202502 seed financing round €8m led by Carma Fund + RV Invest |
2025-02-04 |
| Bureau Veritas–SGS: investment, 202501– confirmed merger discussion |
2025-01-15 |
| Owlstone–Aviva: investment, 202501 financing round Series E first closing totalling $27m incl existing + co-investor Aviva Ventures |
2025-01-15 |
| Owlstone–Gates Foundation: grant, 202404– initial $1.5m grant to develop breat-based diagnostics for developing countries from Gates Foundation |
2025-01-15 |
| Owlstone–Horizons Ventures: investment, 202501 financing round Series E first closing totalling $27m incl existing + co-investor Horizon Ventures |
2025-01-15 |
| Owlstone–SEVERAL: investment, 202501 financing round Series E first closing $27m led by Ventura Capital |
2025-01-15 |
| Owlstone–Ventura Capital: investment, 202501 financing round Series E first closing totalling $27m incl existing + lead investor Ventura Capital |
2025-01-15 |
| SpinChip Diagnostics–Mérieux: investment, 202501– acquisition of remaining 80% of SpinChip for €111m in cash by bioMérieux |
2025-01-13 |
| Syncell–SEVERAL: investment, 202412 financing round Series A $15m led by Taiwania Capital Bio Fund bringing total raised to $30m |
2024-12-11 |
| Syncell–Taiwania Capital: investment, 202412 financing round Series A totalling $15m incl lead investor Taiwania Capital Bio Fund |
2024-12-11 |
| HexagonFab–Merck (DE): investment, 202412 financing round Series A totalling £6.6m of Abselion incl lead investor M Ventures |
2024-12-04 |
| HexagonFab–SEVERAL: investment, 202412 financing round Series A £6.6m of Abselion led by M Ventures |
2024-12-04 |
| miDiagnostics–Alychlo: investment, 202412 financing round Series D totalling €30m incl existing + co-investor Alychlo |
2024-12-04 |
| miDiagnostics–Pamica: investment, 202412 financing round Series D totalling €30m incl existing + co-investor Pamica |
2024-12-04 |
| miDiagnostics–SEVERAL: investment, 202412 financing round Series D €30m led by Thermo Fisher Scientific |
2024-12-04 |
| miDiagnostics–Thermo Fisher: investment, 202412 financing round Series D totalling €30m incl lead investor Thermo Fisher Scientific |
2024-12-04 |
| miDiagnostics–VMF Invest: investment, 202412 financing round Series D totalling €30m incl existing + co-investor VMF Invest |
2024-12-04 |
| Bico–RAG: investment, 202411 acquisition €26m of Nanoscribe from Bico Group by LAB14 GmbH |
2024-11-21 |
| PrognomiQ–aMoon: investment, 202411 financing round Series D totalling $34m incl existing + co-investor aMoon |
2024-11-05 |
| PrognomiQ–Bruker: investment, 202411 financing round Series D totalling $34m incl existing + co-investor Bruker |
2024-11-05 |
| PrognomiQ–Catalio Capital: investment, 202411 financing round Series D totalling $34m incl existing + co-investor Catalio Capital Management |
2024-11-05 |
| PrognomiQ–Invus Group: investment, 202411 financing round Series D totalling $34m incl existing + co-investor Invus |
2024-11-05 |
| PrognomiQ–OTHER: investment, 202411 financing round Series D totalling $34m incl new large strategic diagnostics investor |
2024-11-05 |
| PrognomiQ–SEVERAL: investment, 202411 financing round Series D $34m led by Seer Inc |
2024-11-05 |
| Bureau Veritas–Mérieux: investment, 202410– acquisition €360m of global food testing of Bureau Veritas by Mérieux NutriSciences |
2024-10-07 |
| Dynamic Biosensors–Bruker: investment, 202410 acquisition €na of Dynamic Biosensors GmbH + integration in Bruker Biosensors business |
2024-10-02 |
| Ion Opticks–Adelis Equity Partners: investment, 202409 strategic investment by Adelis Equity Partners |
2024-09-10 |
| Alphalytik Pharmaservice–Certania: investment, 202409 acquisition of Alphalytik Pharmaservice GmbH by Certania |
2024-09-04 |
| Irubis–SEVERAL: investment, 202408 financing round pre-Series A led by new investor BioProcess360 Partners |
2024-08-29 |
| mzio–Bremen (govt): grant, 202408 grant funding €150k from BAB co-funded by EU |
2024-08-21 |
| Genedata–Danaher: investment, 202408 acquisition of Genedata that will join Danaher’s Life Science segment |
2024-08-19 |
| Novalix–Bruker: investment, 202408 strategic minority investment €na by Bruker |
2024-08-07 |
| Agilent–Sigsense Technologies: lab management software, 202407 supply existent Sigsense technology available via Agilent CrossLab Connect |
2024-07-29 |
| Sigsense Technologies–Agilent: investment, 202407 acquisition €na of Sigsense by Agilent |
2024-07-29 |
| Biovectra–Agilent: investment, 202407– acquisition of Biovectra for $925m by Agilent from H.I.G. Capital |
2024-07-22 |
| CytoReason–Thermo Fisher: investment, 202407 financing round totalling $80m incl investor Thermo Fisher Scientific |
2024-07-17 |
| OHMX.bio–Anacura: investment, 202407 acquisition of OHXM.bio by Anacura |
2024-07-04 |
| Enantios–SEVERAL: investment, 202407 seed financing round >CHF1.8m led by Privilège Ventures |
2024-07-01 |
| CatSci–Keensight Capital: investment, 202406 additional investment? by Keensight to support acquisition of Reach Separations by CatSci |
2024-06-25 |
| Reach Separations–CatSci: investment, 202406 acqusition of Reach Separations by CatSci Ltd with support from Keensight Capital |
2024-06-25 |
| Owlstone–Gates Foundation: investment, 202501 financing round Series E first closing totalling $27m incl $5m from new + co-investor Gates Foundation |
2024-04-25 |
| NanoString–Bruker: investment, 202404– acquisition $392.6m of substantially all assets winning bid under Bankruptcy Code |
2024-04-17 |
| IsoSpec Analytics–Another.vc: investment, 202404 pre-seed financing round totalling $1.9m incl co-investor Another.vc |
2024-04-16 |
| IsoSpec Analytics–Founderful: investment, 202404 pre-seed financing round totalling $1.9m incl lead investor Founderful |
2024-04-16 |
| IsoSpec Analytics–SEVERAL: investment, 202404 pre-seed financing round $1.9m led by Founderful |
2024-04-16 |
| IsoSpec Analytics–Tiny.vc: investment, 202404 pre-seed financing round totalling $1.9m incl co-investor Tiny.vc |
2024-04-16 |
| IsoSpec Analytics–Venture Kick: investment, 202404 pre-seed financing round totalling $1.9m incl co-investor Venture Kick |
2024-04-16 |
| NanoString–Patient Square Capital: investment, 202403–202404 stalking horse bid $220m for assets under Bankruptcy Code NOT REALISED |
2024-03-10 |
| Tagomics–SEVERAL: investment, 202402 financing round £6.7m led by Calculus Capital |
2024-02-21 |
| Tagomics–SEVERAL: investment, <202402 pre-seed financing round £1.6m (incl grant from Innovate UK) |
2024-02-21 |
| Chemspeed–Bruker: investment, 202401– acquisition €na of Chemspeed Technology AG by Bruker |
2024-01-25 |
| Nion–Bruker: investment, 202401 acquisition $23m of Nion by Bruker |
2024-01-03 |
| LumiraDx–Roche: investment, 202312– acquisition $295m + $55m milestones of parts of LumiraDx Group related to innovative PoC technology |
2023-12-29 |
| Elitech–Bruker: investment, 202312– acquisition €870m in cash of Elitech Group from PAI Partners SIGNED Put Option Letter |
2023-12-23 |
| Tome Biosciences–SEVERAL: investment, 202312 financing rounds Series A + B $213m announced at launch |
2023-12-12 |
| Oxford Nanopore–Mérieux: investment, 202310 investment £69.1m purchase of 29m ordinary shares at £2.38/share by bioMérieux |
2023-10-19 |
| Olink–Thermo Fisher: investment, 202310– acquisition cash tender offer $3.1b at $26/share by Thermo Fisher |
2023-10-17 |
| MIRO Analytical–Bruker: investment, 202310 majority investment €na by Bruker |
2023-10-04 |
| SomaLogic–Standard BioTools: investment, 202310–202401 reverse merger with former SomaCare shareholders owning 57% of combined company |
2023-10-04 |
| Agilent–Exact Sciences: investment, 202309– acquisition €na of Resolution Bioscience by Exact Sciences from Agilent |
2023-09-12 |
| Abcam–Danaher: investment, 202308– acquisition $24/share in cash = enterprise value $5.7b incl assumed indebtedness + net of acquired cash |
2023-08-28 |
| PhenomeX–Bruker: investment, 202308–202310 acquisition cash tender offer $108m by Bruker at $1/share |
2023-08-17 |
| NuChem Sciences–Sygnature Discovery: investment, acquisition of NuChem Sciences by Sygnature Discovery |
2023-07-31 |
| Tome Biosciences–Bruker: investment, 202312 financing rounds Series A + B totalling $213m incl $10m from investor Bruker Corp 7/23 |
2023-07-26 |
| Interherence–Bruker: investment, 202307 acquisition $17.3m of Interherence GmbH by Bruker |
2023-07-03 |
| Hema.to–SEVERAL: investment, 202306 seed financing round €3.6m with Elaia Partners + Heal Capital + HTGF |
2023-06-26 |
| Lunaphore–Bio-Techne: investment, 202306–202307 acquisition $170.1m of Lunaphore by Bio-Techne |
2023-06-22 |
| Ellab–Novo Group: investment, 202306– acquisition of Ellab by Novo Holdings from EQT Private Equity + co-shareholders |
2023-06-21 |
| DNTox–SEVERAL: investment, 202306 seed financing round €1.4m led by HTGF |
2023-06-14 |
| Zontal–Bruker: investment, 202305 acquisition $14.8m of Zontal by Bruker |
2023-05-08 |
| Pinpoint Testing–Bruker: investment, 202303 acquisition $8.6m of Pinpoint Testing LLC by Bruker |
2023-03-28 |
| e-MSion–Agilent: investment, 202303 acquisition of e-MSion by Agilent |
2023-03-09 |
| Fasmatech–Bruker: investment, 202303 acquisition $10.3m of Fasmatech by Bruker |
2023-03-03 |
| Astrea Bioseparations–Biotage: investment, 202302– acquisition $190m in shares + $45 cash milestones of Astrea from Gamma Biosciences (KKR) |
2023-02-15 |
| Biotage–KKR: investment, 202302– investment $25m tog with sale of Astrea Bioseparations by Gamma for shares resulting in 17% share in Biotage of Gamma |
2023-02-15 |
| Wyatt Technology–Waters: investment, 202302–202305 acquisition $1.36b in cash of Wyatt by Waters |
2023-02-15 |
| SAMDI Tech–Charles River: investment, 202301 acquisition of remaining 80% not already owned for $50m in cash by Charles River |
2023-01-30 |
| InDevR–Adjuvant Capital: investment, 202301 financing round Series B totalling $9m incl $4m from Adjuvant Capital |
2023-01-17 |
| InDevR–Mérieux: investment, 202301 financing round Series B totalling $9m incl $5m from bioMérieux in connection w partnership |
2023-01-17 |
| InDevR–SEVERAL: investment, 202301 financing round Series B $9m from bioMérieux + Adjuvant Capital |
2023-01-17 |
| Delta Precision–Astrea Bioseparations: investment, 202301 acquisition of Delta Precision Ltd by Astrea |
2023-01-09 |
| Evosep–Novo Group: investment, 202301 minority investment of $40m by Novo Holdings A/S |
2023-01-09 |
| Acquifer Imaging–Bruker: investment, 202301 acquisition $7.6m of Acquifer Imaging Gmbh + subsidiary Deltabyte GmbH by Bruker |
2023-01-05 |
| Biognosys–Bruker: investment, 202301 acquisition $73.6m of majority share in Biognosys by Bruker |
2023-01-04 |
| IsoPlexis–Berkeley Lights: investment, 202212–202303 merger acquisition $57.8m in shares with former Berkeley owners holding 75.2%, renamed PhenomeX |
2022-12-21 |
| Numares–EU (govt): credit, 202212– quasi-equity venture debt financing up to €20m from EIB |
2022-12-20 |
| Numares–SEVERAL: investment, 202212 financing round €20m from existing investors |
2022-12-20 |
| Variolytics–SEVERAL: investment, 202212 seed financing round €7-digit from HTGF + FTTF + business angels |
2022-12-07 |
| Cellesce–Danaher: investment, 202212 acquisition of Cellesce by Molecular Devices |
2022-12-06 |
| Neurescence–Bruker: investment, 202211–202212 acquisition 100% of Neurescence Inc by Bruker |
2022-11-14 |
| Elemental Machines–SEVERAL: investment, 202211 financing round Series B $41m led by Sageview Capital |
2022-11-10 |
| Inscopix–Bruker: investment, 202211 acquisition $101.5m of Inscopix by Bruker |
2022-11-08 |
| Binding Site–Thermo Fisher: investment, 202210– acquisition £2.25b in cash from shareholder group led by Nordic Capital ANNOUNCED |
2022-10-31 |
| MS-Omics–Clinical Microbiomics: investment, 202210 acquisition of MS-Omics ApS by Clinical Microbiomics A/S |
2022-10-17 |
| Cevec–Danaher: investment, 202210 acquisition of Cevec by Cytiva |
2022-10-06 |
![[MSC] Mass-Spec-Capital.com The Mass Spectrometry Web Portal](/images/basics/msc-mass-spec-capital-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
